专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07494975B2 Anti-HIV composition, production method thereof and medicament 有权
标题翻译：抗HIV组合物及其制备方法及药物
公开(公告)号：US07494975B2
公开(公告)日：2009-02-24
申请号：US10509686
申请日：2003-04-17
申请人： Romain Vives , Quentin Sattentau , Claudio Vita , Hugues Lortat-Jacob
发明人： Romain Vives , Quentin Sattentau , Claudio Vita , Hugues Lortat-Jacob
IPC分类号： A61K38/16 , C07K1/00 , C07K14/00 , C07K17/00 , C08B37/10
CPC分类号： C07K16/1063 , A61K31/727 , A61K38/1774 , A61K39/40 , A61K45/06 , C07K2317/32 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to an anti-HIV composition and to the method for producing it.The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the group consisting of heparin, heparan sulphate, and a polyanion equivalent to heparin or to heparan sulphate. The molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein is a CD4 peptide or a derivative thereof.The present invention also relates to the use of said composition for producing a medicinal product, in particular a medicinal product intended for the treatment of AIDS.
摘要翻译：本发明涉及抗HIV组合物及其生产方法。本发明的组合物包含聚阴离子和能够诱导gp120病毒蛋白的CD4i表位暴露的分子。聚阴离子可以选自例如肝素，硫酸乙酰肝素和等同于肝素的聚阴离子或硫酸肝素。能够诱导gp120病毒蛋白质的CD4i表位暴露的分子是CD4肽或其衍生物。本发明还涉及所述组合物用于生产药物，特别是用于治疗AIDS的药物的用途。

2. 发明申请

US20060084593A1 Anti-hiv composition, production method thereof and medicament 有权
标题翻译：抗组成，其制备方法和药物
公开(公告)号：US20060084593A1
公开(公告)日：2006-04-20
申请号：US10509686
申请日：2003-04-17
申请人： Romain Vives , Quentin Sattentau , Claudio Vita , Hugues Lortat-Jacob
发明人： Romain Vives , Quentin Sattentau , Claudio Vita , Hugues Lortat-Jacob
IPC分类号： A61K38/16 , C07K14/16 , C08B37/10
CPC分类号： C07K16/1063 , A61K31/727 , A61K38/1774 , A61K39/40 , A61K45/06 , C07K2317/32 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to an anti-HIV composition and to the method for producing it. The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the group consisting of heparin, heparan sulphate, and a polyanion equivalent to heparin or to heparan sulphate. The molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein is a CD4 peptide or a derivative thereof. The present invention also relates to the use of said composition for producing a medicinal product, in particular a medicinal product intended for the treatment of AIDS.
摘要翻译：本发明涉及抗HIV组合物及其生产方法。本发明的组合物包含聚阴离子和能够诱导gp120病毒蛋白的CD4i表位暴露的分子。聚阴离子可以选自例如肝素，硫酸乙酰肝素和等同于肝素的聚阴离子或硫酸肝素。能够诱导gp120病毒蛋白质的CD4i表位暴露的分子是CD4肽或其衍生物。本发明还涉及所述组合物用于生产药物，特别是用于治疗AIDS的药物的用途。

3. 发明申请

US20090297551A1 ADJUVANT 审中-公开
公开(公告)号：US20090297551A1
公开(公告)日：2009-12-03
申请号：US12293380
申请日：2007-03-19
申请人： Quentin Sattentau , Neil Sheppard
发明人： Quentin Sattentau , Neil Sheppard
IPC分类号： A61K39/00 , A61K47/06 , A61K45/00 , A61K39/12 , A61K39/21 , A61K39/245 , A61K39/095 , A61K39/118 , A61K39/02 , A61P37/04
CPC分类号： A61K39/39 , A61K39/12 , A61K39/21 , A61K2039/54 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/55516 , A61K2039/55561 , A61K2039/55566 , A61K2039/575 , C07K14/005 , C12N2740/16122 , C12N2740/16134
摘要： This invention relates to a novel adjuvant comprising a transfection reagent, and to uses of this adjuvant. In particular, the adjuvant may be used in compositions for eliciting an immune response and in vaccines.
摘要翻译：本发明涉及包含转染试剂的新型佐剂，以及该佐剂的用途。特别地，佐剂可用于引发免疫应答和疫苗的组合物中。

4. 发明申请

US20070110759A1 Methods 审中-公开
标题翻译：方法
公开(公告)号：US20070110759A1
公开(公告)日：2007-05-17
申请号：US11434320
申请日：2006-05-11
申请人： Quentin Sattentau , Peter Openshaw , Amin Moghaddam , Wieslawa Olszewska
发明人： Quentin Sattentau , Peter Openshaw , Amin Moghaddam , Wieslawa Olszewska
IPC分类号： A61K39/00 , C08B37/00 , C07K14/82
CPC分类号： A61K39/00 , A61K39/35 , A61K2039/57
摘要： The presence of aldehydic groups on proteins and lipoproteins is associated with various pathological conditions such as atherosclerosis, diabetes and alcoholic liver disease. Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants and the elderly. RSV vaccine research has been impeded because a formalin-inactivated vaccine used in the 1960s predisposed infants to enhanced disease following subsequent natural infection. The molecular basis for the vaccine-induced hypersensitivity has not, however, been elucidated. We show here that addition of reactive carbonyl groups to ovalbumin (OVA) by treatment with glycolaldehyde or formaldehyde increases the protein's immunogenicity in mice, and biases the immune response towards a Th2-type response. The increased immunogenicity and the Th2-type response can both be abrogated by reductive elimination of the reactive carbonyl groups. We demonstrate that RSV inactivated by formaldehyde (FI-RSV), following a protocol used previously to prepare the vaccine, contains reactive carbonyl groups. Using a well-established model of FI-RSV vaccine-induced pathology, immunisation of mice with FI-RSV and subsequent challenge of the mice with live RSV induced Th2-type responses, lung eosinophilia and weight loss that were abrogated by reductive elimination of the reactive carbonyl groups. We thus propose that the addition of reactive carbonyl groups to RSV during inactivation is the major mechanism that drives the Th2-immune response and associated pathology. Moreover, we suggest that the addition of reactive carbonyl groups to other antigens, including vaccines, may be responsible for other hypersensitive and allergic reactions described in the literature.
摘要翻译：蛋白质和脂蛋白上醛基的存在与各种病理状况如动脉粥样硬化，糖尿病和酒精性肝病有关。呼吸道合胞病毒（RSV）是婴幼儿严重呼吸系统疾病的主要原因。 RSV疫苗研究受到阻碍，因为二十世纪六十年代使用的福尔马林灭活疫苗使婴儿在随后的自然感染后发生增强的疾病。然而，疫苗诱导的超敏反应的分子基础尚未阐明。我们在这里显示，通过用乙醇醛或甲醛处理向卵白蛋白（OVA）中加入反应性羰基增加了蛋白质在小鼠中的免疫原性，并且将免疫应答偏向Th2型反应。增加的免疫原性和Th2型反应都可以通过还原性消除反应性羰基来消除。我们证明根据以前用于制备疫苗的方案，由甲醛（FI-RSV）灭活的RSV含有活性羰基。使用FI-RSV疫苗诱导的病理学的成熟模型，用FI-RSV免疫小鼠，随后用活RSV诱导的Th2型反应对小鼠进行攻击，肺嗜酸粒细胞增多和体重减轻，通过还原消除反应性羰基。因此，我们建议在灭活期间向RSV中添加活性羰基是驱动Th2免疫应答和相关病理学的主要机制。此外，我们建议向其他抗原（包括疫苗）添加活性羰基可能是文献中描述的其他过敏反应和过敏反应的原因。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式